Angiotensin receptor blockers: how important is selectivity?
about
Comparing angiotensin II receptor blockers on benefits beyond blood pressurePharmacological and clinical profile of moexipril: a concise review.Changes in levels of angiotensin II and its receptors in a model of inverted stress-induced cardiomyopathy.Angiotensin AT2 receptors: cardiovascular hope or hype?Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.Pharmacological profile and clinical use of moexipril.Prenatal programming of angiotensin II type 2 receptor expression in the rat.Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan.Left ventricular hypertrophy--the problem and possible solutions.Class effects and labeling of antihypertensive drugs.Comparative assessment of angiotensin receptor blockers in different clinical settings.A review of the use of angiotensin receptor blockers for the prevention of cardiovascular events in patients with essential hypertension without compelling indications.Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.Renin-angiotensin system inhibitors in patients with coronary artery disease who have undergone percutaneous coronary intervention.Effect of angiotensin II and endothelin-1 receptor blockade on the haemodynamic and hormonal changes after acute blood loss and after retransfusion in conscious dogs.Prenatal exposure to interleukin-6 results in hypertension and alterations in the renin-angiotensin system of the rat.Expression of angiotensin II and its receptors in cyclosporine-induced gingival overgrowth
P2860
Q30360678-4DF07287-8C96-4072-8C42-D411C2E4A2AFQ34549738-0E13F352-40FF-4E93-9449-6DC62D37F162Q34558461-A02F7962-AE43-4624-B598-CF33C5D0F066Q35045801-19961B0E-5E74-404E-AB6A-C4B926427193Q35688193-3742A5AD-72AA-4397-BECA-88977C2D4CCBQ35696268-016C65B7-D3F2-40D3-A241-3945AD9DBA68Q35841439-BE139C49-5285-4ED6-9DC2-309C71F46B50Q36014340-5127D72B-0F44-410C-9330-DD0A57447013Q36285368-4C48504E-9A58-4CBD-9095-C4893A04567CQ36416119-2DADA180-1869-4CFF-9B0B-5CE73A83A37FQ37649519-7A26A565-E235-44D9-B76D-44137C1C7AD8Q38098985-51E76122-A8A0-42D2-8A9A-F3D6F0DF8B95Q38258427-B64868BF-88C3-4897-AAA2-5BBA821F67A3Q38835716-EAA022C2-F672-45C7-84D3-61634B04B0B5Q44804932-B4E637F4-3E3C-42D9-A7D6-B4C0C7CBF08FQ51796679-3365C2E9-7895-4A52-96EE-D9C3FA71AEEEQ56529178-2F01CDA7-FBBD-48CE-9C13-E8AE9A7222B0
P2860
Angiotensin receptor blockers: how important is selectivity?
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Angiotensin receptor blockers: how important is selectivity?
@ast
Angiotensin receptor blockers: how important is selectivity?
@en
type
label
Angiotensin receptor blockers: how important is selectivity?
@ast
Angiotensin receptor blockers: how important is selectivity?
@en
prefLabel
Angiotensin receptor blockers: how important is selectivity?
@ast
Angiotensin receptor blockers: how important is selectivity?
@en
P1476
Angiotensin receptor blockers: how important is selectivity?
@en
P2093
Helmy M Siragy
P304
P356
10.1016/S0895-7061(02)02280-X
P577
2002-11-01T00:00:00Z